While semaglutide remains an option, our new Tirzepatide protocol offers faster results at a significantly more accessible price point
Historically, obesity was stigmatized and under-treated, often perceived as a result of poor lifestyle choices rather than as a complex metabolic condition
Following the recommended intake can help maintain consistent antioxidant support
Natural sources of peptides include milk, meat, eggs, fish, soy, beans and lentils, oats, hemp seeds, flaxseed, and wheat
These include: Diuretics (furosemide, hydrochlorothiazide) which can exacerbate volume depletion ACE inhibitors or ARBs (lisinopril, losartan) which may cause acute kidney injury when combined with dehydration NSAIDs (ibuprofen, naproxen) which reduce kidney blood flow SGLT2 inhibitors (empagliflozin, dapagliflozin) which cause osmotic diuresis, though these medications have proven renal and cardiovascular benefits and should not be discontinued without medical advice Advanced age (over 65 years) and cardiovascular disease also increase vulnerability to kidney injury
Phase 2 data published in the New England Journal of Medicine (2023) demonstrated substantial weight loss in adults with obesity, but the medicine is not yet approved for clinical use in the UK
